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Introduction
National and international drug markets feature frequent 
changes in the price and purity of illicit drugs (Australian 
Criminal Intelligence Commission 2019; European Monitoring 
Centre for Drugs and Drug Addiction 2018; United Nations 
Office on Drugs and Crime 2018). For example, the average 
price of cocaine per gram in the United States decreased 
more than threefold between 1977 and 1989, from US$316 
to US$97 (Caulkins 2001). There can be even greater variation 
over the short term—for example, the retail purity of heroin sold 
in New South Wales varied between 13 and 80 percent over 
a two-year period (Weatherburn et al. 1995). International 
research has further shown that price and purity can shape 
drug consumption and in turn drug-related harm. For 
example, Caulkins (2001) showed that the fall in the retail 
price of pure cocaine in the United States was associated 
with increased cocaine-related emergency department (ED) 
presentations. However, there remains limited understanding 
of the universality of the relationship—that is, to what extent 
relationships between price, purity and drug-related harm 
vary by place, time and drug type. Clarifying the relationship 
is important to inform targeted law enforcement and harm 
minimisation strategies, and illicit drug monitoring systems.
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This project aimed to review existing research that has examined the relationship between price, 
purity and drug-related harm at the population level. More specifically, it aimed:
 • to examine the relationship between retail-level price and purity, and seven population level drug-
related harms (ambulance call-outs, ED presentations, hospital admissions, treatment admissions, 
fatal and non-fatal overdoses, property crime, and violent crime); 
 • to identify differences in the relationship between price, purity and harm across three drug types: 
heroin, cocaine and meth/amphetamine; and 
 • to identify factors that may moderate these relationships.
Price and purity in illicit drug markets
As outlined by Caulkins and Reuter (1998), there are many reasons why it is important to understand 
price and purity in illicit drug markets. Firstly, it helps us understand whether and how illicit drug 
markets differ to other illicit and licit markets. Here research has shown that the price of illicit drugs 
is extraordinarily high—particularly given drugs are relatively inexpensive to make, with much of their 
mark-up compensating for the risks of criminal sanctions or theft and violence from other market 
players (Reuter & Kleiman 1986). Secondly, price and purity data can inform analysis of the impacts of 
enforcement (Bright & Ritter 2010; Caulkins & Reuter 1998). Evidence suggests that law enforcement 
tends to have short-term rather than long-term impacts (Bright & Ritter 2010). Herein we focus on a third 
application—impacts of price and purity on drug-related harms, both health and criminal justice related. 
Several concepts and assumptions underpin this work. The first is that people who use drugs are 
price-sensitive—that is, there is elasticity of demand: when prices increase, consumption decreases. 
Numerous studies have found changes in consumption as a result of changes in price, and that 
these changes occur in non-dependent and dependent populations and across multiple illicit drugs 
(Caulkins 2007; Gallet 2014; Rhodes et al. 2000). The second assumption is that drug consumption 
is associated with harm, and that price-driven changes in consumption will influence harms. Again, 
a clear body of work shows the multiple harms associated with drug consumption such as overdose, 
property crime and violence (Babor et al. 2018; Degenhardt et al. 2013). Given that around 20 percent 
of people consume around 80 percent of drugs, harms are most notable among people who are 
drug dependent or who consume drugs regularly. For example, in Australia the annual social cost of 
health, crime and road accidents for someone who is opiate dependent is estimated to be $105,342, 
compared to $1,965 for someone who is non-dependent (Moore 2007). 
Third, consistent with basic economic theory, we anticipate that the relationship between price and 
harms will vary according to the outcome of interest and the length of time since the price or purity 
changed. For health harms (eg overdose) we anticipate that, if price increases, consumption and 
associated health harms will fall, and that this relationship will hold over the short and long term. 
For treatment outcomes, we anticipate that, if price increases, treatment admissions will fall, but the 
relationship will be shaped by the supply of treatment, including levels of funding, availability and quality. 
For impacts on drug-related crime, as outlined by Caulkins and Reuter (1998) we expect the relationship 
will be ambiguous. This is because increased price may lead to more property crime to support 
purchasing at higher prices. However, if people who use drugs are more sensitive to price, then increased 
price may lead to reduced property crime due to declines in consumption among heavy users. Similar 
arguments can be made in relation to violence. Economic theory also suggests impacts on drug-related 
crime and treatment may differ in the short and long run due to delays in behavioural adaptation.
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A further important principle is the difference between price, purity and purity-adjusted price (PAP). 
The actual value of an illicit drug is a function of the quantity purchased, the price paid and the purity 
of the drug (Caulkins 2007). As such, even when prices unadjusted for purity are quite flat (see, for 
example, the Illicit Drug Reporting System and Ecstasy and Related Drug Reporting System price series 
for Australia, in which price has been remarkably stable over many years; Peacock et al. 2018) this can 
mask large variations in the purity of the drug. This was clearly demonstrated during the Australian 
heroin shortage, when the price of heroin in Victoria increased from $300 per gram in 2000 to $450 
in 2001—a 50 percent increase—but purity declined from 46 percent to 16 percent, meaning PAP for 
heroin increased by 325 percent (Caulkins 2007). For this reason, the strongest evidence comes from 
studies measuring PAP, not price or purity alone.
Finally, it is important to distinguish between (a) the relationship between PAP and harm (eg inverse 
or direct) and (b) the impacts on harm (eg increased or reduced), as impacts are shaped by both 
the relationship between PAP and harm and the trends in PAP. For example, if there is an inverse 
relationship and PAP is decreasing, harms will increase, but if there is an inverse relationship and PAP 
is increasing, harms will reduce.
Method
This study employed a rapid review methodology—a form of evidence synthesis that provides a 
rigorous method for locating, appraising and synthesising evidence from previous studies, and 
producing results in a timelier manner than a systematic review (Ganann, Ciliska & Thomas 2010). 
Consistent with rapid review methodologies, this study was designed in consultation with end users 
(the Australian Institute of Criminology), used a limited number of electronic databases (five), and 
involved tight inclusion criteria and one principal coder. A potential limitation of a rapid review is that 
some studies may not be identified; however, this can be mitigated by including grey literature as well 
as journal articles and by consulting experts in relation to the included literature (Ganann, Ciliska & 
Thomas 2010). Both steps were adopted for this review (see below).
Search strategy
The search strategy involved four stages. First, comprehensive searches were conducted in five 
databases of peer-reviewed articles: Web of Science, PsycINFO, MEDLINE, Scopus, and Criminal 
Justice Abstracts. Search terms were specified based on the research questions, as follows:
 • price OR purity; (AND) drug OR heroin OR cocaine OR amphetamine OR methamphetamine; (AND) 
overdose OR ambulance OR emergency OR hospital OR property OR violent OR crime; (AND) 
effect* OR impact* OR relationship) 
 • (NOT) pharma* OR medic*
Second, we manually searched for grey literature via the websites of the International Society for the 
Study of Drug Policy, National Drug Law Enforcement Research Fund, European Monitoring Centre for 
Drugs and Drug Addiction and RAND Corporation. Third, we used Google Scholar to identify relevant 
studies that had cited those identified in the first two stages. Finally, three international experts were 
consulted to identify other relevant studies. The search resulted in identification of 1,988 records, all 
of which were screened for inclusion. This screening process resulted in 85 full-text articles that were 
assessed for eligibility and 36 that were included in the analysis (Figure 1).
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Figure 1: Search results
1,088 records screened for 
relevance (�tle/abstract)
85 full-text ar�cles 
assessed eligibility
36 studies included for 
analysis
1,088 records a�er duplicates removed
1,967 records iden�fied through 
database searching 
Web of Science = 1,040
Scopus = 866
Criminal Jus�ce Abstracts = 53
MEDLINE = 5
PsycINFO = 3
21 addi�onal records iden�fied through 
other sources
Select websites = 2
Forward cita�on checks = 12
Content experts = 7
1,003 records 
excluded




Inclusion and exclusion criteria were developed with a focus on including empirical, quantitative 
studies related to drug prices, purity and at least one of the population level harms specified above. 
The searches were limited to studies examining heroin, cocaine and meth/amphetamine and 
excluded studies examining cannabis or other drugs. Only studies published in the English language 
between 1990 and March 2019 (when the searches were conducted) were included. Opinion pieces, 
commentaries and qualitative studies were also excluded.
Literature was excluded if it examined drug price or purity in the absence of any focus on harm—for 
example, studies focusing on the price elasticity of demand or the relationship between price, purity 
and drug consumption. The focus on harms meant that this review was intrinsically biased towards 
impacts from heavy use rather than occasional use, but this was consistent with our research 
questions. Harm is also the outcome of most concern to policymakers (Dave 2006).
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Data extraction and synthesis
A data extraction spreadsheet was used to ensure that consistent information was coded from each 
study, including:
 • study description—authors, title, journal/source, publication year, study aim, drug type(s),  
drug form(s);
 • context—location, time period of analysis, other;
 • methods—study design, data source for price and purity information, PAP (yes/no), data source 
for outcome(s); 
 • price and purity—trends in raw price, raw purity and PAP;
 • effect—nature of relationship between PAP and drug-related harm (inverse, direct, mixed, null);
 • impact on drug-related harms—impact on ambulance attendances, ED visits, hospital admissions, 
treatment admissions, fatal and non-fatal overdose, property crime, violent crime, drug 
possession and supply offences (increased, reduced, mixed, null); and quantitative effect size; and
 • other—key findings/implications, moderators/mediators.
This spreadsheet (available at https://ndarc.med.unsw.edu.au/project/relationship-between-price-
purity-and-population-level-drug-related-harm) became the basis for data analysis and synthesis, 
with referral back to the original articles as required.
Results
Study characteristics
Of the 36 included studies, 47 percent were from North America (1 from Canada and 16 from the 
United States), with a further 42 percent from Australasia (all from Australia) and 11 percent from 
Europe (including the United Kingdom, Netherlands, Austria and Turkey; Table 1). Most studies 
(67%) focused on heroin. The main data source was law enforcement seizures and 36 percent used 
data from the US System To Retrieve Information from Drug Evidence (STRIDE) or STARLIMS, which 
replaced STRIDE in October 2014. Since 1973 these systems have provided transaction level data 
on undercover buys including the date, city, price, quantity and purity of each buy (for details see 
Caulkins 1994). A further 22 percent used other law enforcement data systems, and one used drug 
checking data. Across the entire sample, only 47 percent of studies employed PAP. 
As outlined in Table 1, there were two main study types—analyses of specific supply events (eg the 
Australian heroin shortage) and non-event analyses focusing on PAP trends over time. These differed 
significantly in method, quality, breadth and location, and hence warranted separate analyses. 
Compared to the event studies (n=18), the non-event analyses (n=18) employed more rigorous study  
designs (econometrics, quasi-experimental or time-series) and were more likely to use PAP (78% vs 17%). 
They also assessed relationships across a broader set of drug types and contexts. Event studies 
tended to assume changes in price and purity based on third-party data, and seldom included price/
purity/PAP data in their analyses.
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Table 1: Characteristics of included studies (n=36)




Event studies  
(n=18)
n % n % n %
Publication year
1995–1999 4 11 4 22 0 0
2000–2005 16 44 3 17 13 72
2006–2010 10 28 6 33 4 22
2011–2019 6 17 5 28 1 6
Continent 
North America 17 47 10 56 7 39
Australasia 15 42 4 22 11 61
Europe 4 11 4 22 0 0
Study design 
Descriptive 3 8 0 0 3 17
Correlational/econometric 12 33 11 61 1 5
Quasi-experimental/time-series 21 58 7 39 14 78
Drug typea
Heroin 24 67 13 72 11 61
Meth/amphetamine 9 25 2 11 7 39
Cocaine 8 22 8 44 0 0
Data source for price and puritya
Law enforcement—STRIDE/STARLIMS 13 36 10 56 3 17
Law enforcement—other 8 22 7 39 1 5
Consumer reports 9 25 4 22 5 28
Expert reports 2 6 0 0 2 11
Drug checking service 1 3 1 5 0  0
No price or purity data presentedb 9 25 0 0 9 50
Employs PAP 17 47 14 78 3 17
Health outcomes examineda
Fatal or non-fatal overdose 12 33 7 39 5 28
Hospital admissions 8 22 5 28 3 17
Emergency department admissions 6 17 5 28 1 6
Ambulance attendance 4 11 1 6 3 17
Treatment outcomes examineda 13 36 4 22 9 50
Crime outcomes examineda
Drug possession and supply offences 8 22 3 17 5 28
Property offences 7 19 1 6 6 33
Violent offences 2 6 1 6 1 6
a: Categories and sub-categories of health, treatment and crime outcomes are not mutually exclusive
b: Event-oriented studies that did not include price or purity data but relied on other studies for context
Trends & issues in crime and criminal justice
Australian Institute of Criminology
7No. 598 July 2020
Findings from non-event studies examining trends over time
Health outcomes
Five US studies examined the relationship between price, purity and PAP and ED admissions. All 
except one (which did not employ PAP: Zhu et al. (2014)) found an inverse relationship between PAP 
and ED admissions (Table A1). This means an increase in PAP was associated with a reduction in ED 
admissions. For example, Dave (2006) found a 10 percent increase in PAP prevented 10,723 cocaine- 
and heroin-related ED visits, with cost savings of $21m to $47m. In one study the inverse relationship 
meant a reduction in PAP was associated with an increase in ED admissions: Davies (2010) found 
a nine percent reduction in average cocaine purity led to 399 more ED admissions per 100,000 
population. Davies found that the level of variance in purity also shapes health outcomes, as higher 
variation in cocaine purity was associated with lower ED admissions. Importantly, Caulkins (2001) 
found trends in PAP accounted for 95 to 98 percent of variation in US ED admissions for cocaine and 
heroin. This shows PAP can be a very strong predictor of this health-related harm.
Three studies examined relationships between PAP and hospital admissions, and all identified that 
reductions in heroin and cocaine PAP were associated with increased hospital admissions for those 
drugs (an inverse relationship). For example, Ciccarone et al. (2016) found that reductions in heroin 
PAP contributed to a doubling in the rate of US hospitalisations for heroin-related skin and soft tissue 
infection (SSTI) admissions. They further concluded that each $100 increase in the yearly average 
price per gram of pure heroin could be associated with a three percent decrease in the rate of heroin-
related SSTI admissions. Ciccarone et al. (2016) also found the source and form of heroin influenced 
hospital admissions, as cities where Mexican black tar heroin dominated (eg San Diego and Seattle) 
had twice the rate of SSTI admissions as cities where Colombian powder heroin dominated (eg Chicago 
and New York). A Dutch study by Brunt et al. (2010) examining hospital admissions over a 17-year 
period found a strong inverse relationship between PAP and cocaine-related harm: as cocaine PAP fell, 
hospital admissions for cocaine increased. But this same study also found changes in amphetamine 
PAP were not associated with changes in hospital admissions for amphetamines. As such we note that 
relationships between PAP and hospital admissions may vary by form, source and drug type.
Eight studies looked at the relationship between PAP and fatal or non-fatal overdoses, with seven 
showing an inverse relationship. The only one that did not find an inverse relationship was one that 
did not adjust prices for purity (Toprak & Cetin 2009). In Australia Moore et al. (2005) found that 
every 10 percent increase in heroin PAP was associated with an 11 percent decrease in the number 
of ambulance calls for non-fatal heroin overdoses, and Darke et al. (1999) found a similar relationship 
between PAP and fatal heroin overdoses. Darke et al. (1999) and Davies (2010) both found that the 
range of heroin purity was an independent predictor of the number of fatalities per fortnight. Hyatt 
and Rhodes (1995) found significant declines in cocaine PAP contributed to a rise in cocaine-related 
fatalities in the United States, a finding that was reproduced by Schifano and Corkery (2008) in the 
United Kingdom for cocaine and crack cocaine. Finally, Unick et al. (2014) found that street price, 
independent of purity, was not associated with heroin overdose, but there was a moderate inverse 
relationship between heroin PAP and heroin overdose (r=−0.17). Specifically, each $100 increase 
in the price per gram of pure heroin resulted in a three percent decrease in the number of heroin 
overdose hospitalisations. Moreover, the reduction in heroin PAP in the US market—from an average 
PAP of US$1,368 per gram in 1993 to US$688 in 2008—accounted for a 20 percent increase in heroin 
overdose hospitalisations.
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Treatment outcomes
Four studies examined impacts on treatment admissions, with variable findings (see Table A2). Brunt 
et al. (2010) found an inverse relationship between PAP and treatment admissions for both cocaine 
and amphetamines (as PAP reduced, treatment admissions rose), with that relationship strongest for 
cocaine. Bach and Lantos (1999) found an inverse relationship, namely that as heroin PAP decreased, 
the doses of opioid agonists used in treatment increased. In contrast, Weatherburn and Lind (1997) 
found no relationship between heroin PAP and treatment admissions, a finding echoed by Schifano 
and Corkery (2008) for cocaine and crack cocaine looking at price and purity separately (not PAP). 
The variability across studies is consistent with economic theory about the large number of factors 
that may affect treatment admissions. While some studies noted differences in the quality of 
treatment offered (Bach & Lantos 1999), none assessed the ease of access to treatment, which other 
research has shown can vary significantly (Ritter, Chalmers & Gomez 2019; Ritter et al. 2019).
Crime outcomes
Three studies examined impacts on crime, and all found an inverse relationship between PAP and 
crime (see Table A3). For example, in the United Kingdom, Schifano and Corkery (2008) found 
reduced price (not adjusted for purity) was associated with increased cocaine and crack cocaine 
offences. The most notable study to test the relationship between PAP and crime was a US study by 
DeSimone (2001) that analysed impacts on seven types of crime: murder and manslaughter, forcible 
rape, aggravated assault, robbery, burglary, larceny, and motor vehicle theft. They observed an 
inverse relationship (increased PAP, decreased crime) for all offences except for aggravated assault, 
which had no relationship, and that the strength of the relationship further differed across the other 
six offence types. DeSimone (2001) demonstrated that the US decline in cocaine PAP in the 1980s 
increased violent and property crime substantially. For example, the average sample price fell from 
US$192 in 1984 to US$69 in 1989, which predicted increases of 52 percent for vehicle theft, 46 
percent for murder, 32 percent for robbery and 17 percent for rape. One limitation is that all studies 
looked at cocaine specifically, which leaves unanswered the question of whether relationships 
between PAP and crime differ by drug type.
Findings from event studies
Australian heroin shortage
Out of the 17 event studies, 11 examined the Australian heroin shortage of early 2001, when there 
was a sudden and dramatic reduction in the availability of heroin in Australia and an accompanying 
change in the retail price and purity of heroin. Consumer reports indicated that in 2001 the retail 
price of heroin increased from $220 to $320 per gram in New South Wales and from $330 to $450 
in Victoria (Day 2004a, 2004b). Prior to 2001, prices had been stable (Mattick, Topp & Degenhardt 
2004). Heroin purity in New South Wales declined from 65 percent to 28 percent between March 
2000 and June 2001, with similar patterns observed in Victoria, South Australia (Day 2004a) and the 
Australian Capital Territory (Smithson et al. 2004). All relevant studies examining the outcomes of the 
heroin shortage are summarised in Table A4.
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Notably, only one study (Weatherburn et al. 2003) employed PAP, with the rest either including purity 
alone or cross-referencing other studies documenting changes in price and purity. This study showed 
that the price per gram of pure heroin in New South Wales rose by 112 percent between 2000 and 
2001, that the rise in PAP was associated with a significant reduction in overdoses (53%), but that 
impacts on property crime (break and enter and robbery) varied over time, as evidenced by a short-
term increase followed by a longer term fall. 
Consistent with Weatherburn et al. (2003), the five other studies examining health outcomes (fatal 
and non-fatal overdoses) also showed an inverse relationship. Specifically, the heroin shortage and 
the accompanying increase in PAP was associated with a significant reduction in fatal and non-fatal 
overdoses in New South Wales, Victoria and the Australian Capital Territory (Degenhardt et al. 2005c, 
2005d, 2005e; Smithson et al. 2004; Weatherburn et al. 2003). The strength of the relationship was 
moderated by age, whereby younger age groups experienced greater declines in overdose than older 
age groups (Degenhardt et al. 2005d). 
Again in keeping with Weatherburn et al. (2003), the three other studies that examined impacts on 
crime found that there was a short-term increase in property offences (including burglary, break-
and-enter dwelling and non-dwelling, and robbery with and without a weapon) in the initial period 
following the shortage (Degenhardt et al. 2005b, 2005e; Smithson et al. 2004). However, the increase 
was not sustained, and acquisitive crime subsequently decreased in New South Wales, Victoria, 
South Australia and the Australian Capital Territory (Degenhardt et al. 2005e; Smithson et al. 2004). 
Geography appeared to moderate the relationship between heroin price and property crime, as the 
strength of the relationships varied across states (highest in NSW, lowest in SA). This was attributed to 
variations in the size and characteristics of the heroin markets. 
Finally, most studies found an inverse relationship between heroin prices and treatment 
outcomes, whereby the heroin shortage was associated with declining numbers of people entering 
pharmacological and non-pharmacological treatment (Degenhardt et al. 2005a, 2005d, 2005e). But 
Smithson et al. (2004) showed that methadone treatment enrolments initially increased and then 
declined, a finding that was also observed in Victoria. No relationship was observed in South Australia.
Methamphetamine precursor controls in North America
Six studies examined a series of methamphetamine precursor controls introduced in North America 
in the 1990s/2000s in response to increasing problems related to methamphetamine use and supply 
(Callaghan et al. 2009; Nonnemaker, Engelen & Shive 2011). The new regulations sought to control 
the wholesale supply and retail sale of pseudoephedrine and ephedrine—the primary precursors 
used in the manufacture of methamphetamine. The US regulations were as follows:
 • 1989—the Chemical Diversion and Trafficking Act (US) regulated wholesale supply of ephedrine 
and pseudoephedrine in bulk powder form. Distributors of these chemicals were required to 
register with the Drug Enforcement Administration and keep records of sales and customers;
 • 1995—the Domestic Chemical Diversion and Control Act (US) partially regulated wholesale 
distribution of products containing ephedrine as the only active medicinal ingredient;
 • 1996—the Comprehensive Methamphetamine Control Act (US) regulated retail sale of products 
that included ephedrine in combination with other active medicinal ingredients (eg cold 
medicines); 
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 • 1997—the Comprehensive Methamphetamine Control Act (US) regulated wholesale supply of 
products that included pseudoephedrine, regardless of whether they contained other active 
medicinal ingredients; and
 • 2000—the California Uniform Controlled Substances Act regulated retail sale by rescheduling 
pseudoephedrine so it was only available behind the counter and in restricted quantities (<9 grams; 
Cunningham & Liu 2008, 2005, 2003; Cunningham, Liu & Callaghan 2009).
The relationships between these precursor controls and price, purity and PAP at the street level were 
studied by several researchers. Cunningham, Liu and Callaghan (2009) used STRIDE data to show the 
mean methamphetamine PAP rose sharply, albeit temporarily, after each of the 1989, 1995 and 1997 
regulations targeting wholesale supply. In contrast, trends differed for the two regulations targeting 
retail sale. The methamphetamine PAP changed little after the 1996 regulation (Cunningham, Liu & 
Callaghan 2009), and fell significantly in California (from US$83.62 to US$59.69 per pure gram) after 
the 2000 regulation (Nonnemaker, Engelen & Shive 2011). 
In line with these trends, Cunningham and Liu (2003) found an inverse relationship (increased PAP 
and reduced drug-related health harms) associated with some but not all reforms. Specifically, they 
showed that the 1989, 1995 and 1997 regulations targeting wholesale supply resulted in a significant 
decline of between 35 percent and 71 percent in methamphetamine-related hospital admissions (see 
also Cunningham & Liu 2008). However, the 1996 regulation targeting retail sales had no effect on 
admissions, a finding that was echoed by Nonnemaker, Engelen and Shive (2011) following the 2000 
reform. Analysis of precursor reforms in Canada also found no inverse relationship in this setting, but 
this study did not employ PAP (Callaghan et al. 2009).
In relation to crime outcomes, Cunningham and Liu (2005) found that methamphetamine arrests 
decreased by approximately 31 to 45 percent when the 1989, 1995 and 1997 regulations were 
implemented, but again these declines were not observed for the 1996 regulation. Finally, Dobkin 
and Nicosia (2009) found an inverse relationship following the 1995 California precursor controls: 
an increase in methamphetamine PAP led to a rapid 50 percent reduction in amphetamine-related 
hospital admissions and felony drug offences and a lagged 35 percent reduction in treatment 
admissions. But there was no compelling evidence of impacts on property or violent crime and all 
impacts were temporary—approaching pre-intervention levels within 18 months. This indicates that 
for precursor controls the type of regulation employed is likely to be a key moderator of impacts on 
PAP and harm. Cunningham and Liu (2005, 2003) and Callaghan et al. (2009) note relationships may 
be shaped by the extent to which regulations adequately target the source(s) of supply (which is why 
wholesale controls may elicit greater desired effects). 
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Discussion
This study involved a rapid review of existing research on the relationship between price, purity and 
drug-related harm at the population level, focusing on seven key outcomes and three drug types. 
Analysis of non-event studies suggests that, with a few exceptions, there is a consistent inverse 
relationship between price, purity and drug-related harm. That is, increased PAP is associated with 
lower harm, and reduced PAP is associated with increased harm. All exceptions can be explained by 
the price series failing to adjust for purity (eg Zhu et al. 2014) or the study’s focus on outcomes for 
which theory predicts effects may differ (eg treatment). In that regard, consistent with economic 
theory, there were subtle differences in outcomes. We saw the clearest relationship with ED 
admissions and overdoses, followed by hospital admissions and crime, while there was no clear 
relationship with treatment.
For event studies the evidence base on the relationship between price, purity and harm was clearly 
less reliable, with the majority (particularly those on the Australian heroin shortage) relying on known 
or assumed changes in price and purity rather than empirical PAP data and its association with harms. 
Nevertheless, these studies also showed that actual or assumed increases in price per pure gram 
were associated with reductions in health-related harms and treatment admissions. Impacts on crime 
varied, as exemplified by reductions following some but not all events, or by short-term increases 
followed by longer term reductions. A further universal finding was that impacts of supply shocks 
dissipated with time.
Across both event and non-event studies we found only subtle differences in the relationship 
between PAP and harm for cocaine and heroin (albeit with a slightly stronger relationship for 
cocaine). There is comparatively little data in this area; hence future research examining relationships 
by drug type is advised, particularly in relation to methamphetamine. Finally, several moderators of 
the relationship were identified, including geography, age, variation or range in purity, drug source, 
drug form and in the case of precursor controls the type of regulation employed. For example, 
changes in PAP appear more likely to influence harm in larger or more established markets and 
among young cohorts. Again, more research is needed to understand these moderators. 
There are several limitations to the analysis, including the limited pool of studies and quantitative 
estimates, and the focus on harms alone. Nevertheless, as the first such review it has important 
implications.
Implications for policy and practice
First, this review shows the value of price and purity data for foreseeing drug market impacts. As 
noted by Caulkins (2001), the relationship between PAP and ED admissions is very strong, accounting 
for 95 to 98 percent of trends in ED admissions. That this appears to hold across health and crime 
harms, multiple drug types and contexts as well as directionality (higher PAP is associated with less 
harm, and lower PAP is associated with greater harm) provides further evidence of the relationship. 
In the context of a rapidly evolving drug market and where there is a multiplicity of drug policy 
options and scarce resources, this is welcome news.
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Second, the review reinforces that PAP rather than price or purity alone influences harm. While there 
can be a strong relationship between PAP and harm, the same harm can have a null or even a counter 
relationship with price or purity alone (particularly price). Analysis of price alone could thus lead to 
erroneous conclusions being drawn. 
Third, the review brings to light the large variability in the quality of research and underlying data 
systems on price and purity, including the data source(s) (eg police, consumers or drug checking 
services), the frequency of data collection, the timeliness of reporting, the ability to match price/
purity/PAP with outcomes of interest and the extent to which systems employ PAP. The predominance 
of evidence (and high-quality evidence) comes from US studies, as a direct consequence of that 
country’s investment in a PAP system (STRIDE/STARLIMS). Routine investment in PAP has a number 
of benefits, including improving understanding of the causes of crime trends and demands on health 
care and criminal justice systems, increasing the ability to foresee future needs, and better informing 
decisions about optimal policy options to increase PAP or keep PAP high. We conclude that PAP should 
form part of routine data collection systems—including in Australia. With that in mind, it is important 
to critically examine the current Australian surveillance and monitoring systems.
Existing Australian systems to monitor drug price, purity and PAP
As of 2020 Australia is fortunate to have several surveillance and monitoring systems that capture 
information on drug price and purity. These include the Illicit Drug Reporting System, the Ecstasy and 
Related Drug Reporting System and Drug Use Monitoring in Australia, which gather information on 
prices paid by people who use drugs, along with their perceptions of drug purity (high, medium, low; 
see, for example, Karlsson & Burns 2018; Patterson, Sullivan & Bricknell 2019; Peacock et al. 2018). 
The data gathered on price is deemed relatively reliable and useful. For example, Weatherburn et 
al. (1995) compared price data from undercover buys with the self-reports of people arrested in 
possession of heroin in Cabramatta; there were no significant differences between the arrest samples 
and the undercover buy samples in either price or PAP. (All heroin samples from undercover officers 
and arrestees were forensically analysed to produce PAP.) But the perceptions of purity gathered by 
the three existing monitoring programs cannot be matched to price, so PAP cannot be derived from 
these sources alone.
The Australian Criminal Intelligence Commission’s Illicit drug data report provides data on prices for 
illicit drugs, collected from each police service based on information supplied by police conducting 
undercover buys and police informants (see, for example, ACIC 2019). Purity data are collected from 
police services and contributing forensic organisations. The limitation here is that analyses vary 
according to police priorities as well as jurisdictional laws, particularly drug trafficking threshold 
laws (Hughes et al. 2014). More specifically, with the exception of Victoria Police’s Forensic Services 
Department, which analyses the size and purity of all drug seizures made in that state, most 
Australian states only analyse the purity of large seizures, and what gets analysed varies across states. 
For example, New South Wales tests the purity of seizures of a commercial quantity or greater, while 
South Australia tests the purity of all samples weighing over five grams irrespective of the drug type 
(Australian Criminal Intelligence Commission 2019). Methamphetamine purity data are thus collected 
on seizures of over 250 grams in New South Wales, over six grams in the Australian Capital Territory 
and over five grams in South Australia. Existing systems thus curtail state comparisons and limit data 
collection on retail-level seizures: the most important data for purity-adjusted price analyses. 
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There are several avenues to improve future analyses in Australia. First, existing high-quality price and 
purity data (eg Victoria Police data), either on their own or in concert with self-report price data from 
people who use drugs, could be better used to produce high-frequency PAP series (see, for example, 
Caulkins 2007; Caulkins, Rajderkar & Vasudev 2010; Scott et al. 2014). Second, law enforcement 
purity data gathered in states other than Victoria could be improved by supplementing purity analysis 
of large seizures with analysis of retail-level seizures, developing consistent measures for forensic 
testing across states, and/or investing in more undercover buys. Alternative data sources such as pill 
testing or drug checking could also be considered.
One motivator for improving data collection is the experience of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), which committed to improving the monitoring of illicit drug 
supply in 2014, most notably by collecting data on price and purity. By 2017, 27 countries reported retail 
purity, and many also reported wholesale purity. The EMCDDA further note that the data collected on 
purity are ‘consistently valuable for the strategic analysis of the European drug market’ (EMCDDA & 
Europol 2018: 11). We similarly argue that improving Australian price and purity analysis (and routinely 
measuring PAP) will increase our capacity to understand the Australian drug market, to address key 
unknowns (such as the extent to which increasing methamphetamine PAP in Australia would reduce 
methamphetamine-related crime) and to identify new avenues to reduce drug-related harm.
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Appendix
Table A1: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Health outcomes

















USA Cocaine ED 
admissions






USA Cocaine ED 
admissions
Yes Inverse As PAP decreased, 
ED admissions 
increased.
Same pattern for both cocaine and 
heroin, but correlation between actual 
and expected ED admissions was 0.987 
for cocaine and 0.975 for heroin. That 
is, price changes explained 97.5% of 
variation in ED admissions for cocaine 
and 95% of variation for heroin, with 
price elasticities of demand being 
estimated at –1.30 and –0.84, 
respectively. 
 Heroin ED 
admissions





USA Cocaine ED 
admissions
Yes Inverse As PAP increased, ED 
admissions fell. 
The elasticity of the probability of an 
ED admission was –0.27 for cocaine 
and –0.10 for heroin. This implied that 
a 10% increase in PAP could prevent 
10,723 cocaine and heroin-related ED 
visits, with cost savings of between 
$21m and $47m.
 Heroin ED 
admissions
Yes Inverse As PAP increased, ED 
admissions fell.
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Table A1: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Health outcomes (cont.)















USA Cocaine ED 
admissions
Yes Inverse Higher average 
purity, higher 
coefficient of 
variance and higher 
skewness (ie longer 
tail in higher purities) 
associated with 
lower ED admissions.
During the 1990s, average cocaine 
purity fell by 9.3 percentage points. 
This translated into 399 more ED 
admissions per 100,000, a 7.6% 
increase relative to the sample mean.
 Heroin ED 
admissions
Yes Inverse Lower coefficient of 
variance and lower 
skewness (but not 
lower average purity) 
associated with 
higher ED admissions.
The decline in heroin purity skewness 
of 0.56 in the 1990s (ie reduction in 
uncertainty in purity) translated into 
766 more ED admissions, a rise of 31% 
relative to the mean.
Zhu et al. 
(2014)





Direct As purity fell, ED 
visits fell.





Null No significant price 
relationship.
Hospital admissions
Brunt et al. 
(2010)
Netherlands Amphetamine Hospital 
admissions
Yes Null Neither purity nor 
PAP had a significant 
impact on hospital 
admissions. 
Important differences observed by 
drug type, with strong negative 
correlation for cocaine PAP and purity 
but not amphetamine.
Amphetamines: PAP β=–0.170 Purity 
β=0.0522




Yes Inverse As PAP and price fell, 
health admissions 
increased.
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Table A1: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Health outcomes (cont.)
















USA Heroin Hospital 
admissions 
for skin and 
soft-tissue 
infections
Yes Inverse As PAP fell, hospital 
admissions rose.
Heroin market features were strongly 
associated with changes in the rate of 
SSTI. Each $100 increase in yearly 
average price per gram of pure heroin 
was associated with a 3% decrease in 
the rate of heroin-related SSTI 
admissions.
Scott et al. 
(2014)
Australia Methamphetamine Hospital 
admissions




Yes Inverse As PAP fell, hospital 
admissions rose. 
Fatal or non-fatal overdose
Moore et 
al. (2005)
Australia Heroin Non-fatal 
overdose
Yes Inverse As PAP rose, non-
fatal overdoses fell. 
Every 10% increase in the PAP of heroin 
was associated with an 11.2% decrease 
in the number of ambulance calls for 
non-fatal heroin overdoses. 
Darke et al. 
(1999)
Australia Heroin Fatal 
overdose
Yes Inverse As PAP increased, 
overdoses fell.
Significant moderate correlation 
(r=0.57) at time lag zero between mean 
purity of heroin sample per fortnight 
and number of overdose fatalities. 
Both mean heroin purity and range of 
heroin purity were independent 





USA Cocaine Fatal 
overdose
Yes Inverse As PAP increased, 
overdoses fell.
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Table A1: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Health outcomes (cont.)













Scott et al. 
(2014)
Australia Methamphetamine Overdose 
deaths
Yes Inverse As PAP fell, overdose 
deaths increased.
 Heroin Overdose 
deaths











Inverse As price fell, deaths 
rose.
The number of cocaine/crack cocaine 
related deaths (deaths from any cause 
where the presence of cocaine/crack 
cocaine was detected) showed a 
year-on-year increase and was inversely 
correlated with price. But the strength 
of relationship differed by form:
 • Cocaine: 0.882***
 • Crack cocaine: –0.569*
Concluded price decrease contributed 
to rise in cocaine-related fatalities.
























USA Heroin Overdose 
admissions 
to hospital
Yes Inverse As PAP fell, 
admissions rose.
Unick et al. 
(2014)
USA Heroin Overdose 
admissions 
to hospital
Yes Inverse As PAP increased, 
overdose admissions 
fell.
No evidence to support the hypothesis 
that actual street price of heroin, 
independent of purity, was associated 
with overdose. But, each $100 increase 
in the price per gram of pure heroin 
results in a 2.9% decrease in the 
number of overdose admissions.
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Table A1: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Health outcomes (cont.)














Risser et al. 
(2007)





Null No relationship 
between purity and 
ambulance call-outs.
Low quality study.
***statistically significant at p<0.001, *statistically significant at p<0.05
Table A2: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Treatment outcomes














Brunt et al. 
(2010)
Netherlands Amphetamine Treatment 
admissions
Yes Inverse As PAP reduced, 
treatment 
admissions rose.
Strong relationship for cocaine and 
moderate relationship for 
amphetamines: 
Amphetamine: PAP β=–5.811* Purity 
β=3.101 
























Null Significant increase in treatment 
admissions not accounted for by 
changes in raw purity or price.
*statistically significant at p<0.05
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Table A3: Key findings from non-event analyses of the relationship between price, purity and drug-related harm: Crime outcomes






















larceny, and motor 
vehicle theft 






Significant impacts across multiple crime 
types:  






Aggravated assault –0.067 
Implies that price increases resulting from 
exogenous supply shifts inversely impact 
both violent and property crime, and that 
the 1980s price decline increased crime 
substantially. For example, the average 
sample price fell from $192 in 1984 to $69 
in 1989. This 178 percent price drop 
predicts increases of 52% for vehicle theft, 
46% for murder, 32% for robbery, 29% for 




UK Cocaine and 
crack cocaine
Drug offences No 
(price 
only)






USA Cocaine % of arrestees 
testing positive to 
drugs
Yes Inverse As PAP reduced, 
% of arrestees 
testing positive 
increased.
***statistically significant at p<0.001, **statistically significant at p<0.01, *statistically significant at p<0.05
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Table A4: Studies examining the Australian heroin shortage and the relationship between price, purity and drug-related harma


















No Inverse As heroin price increased and purity fell, non-fatal overdoses 
decreased significantly as measured by ambulance call-outs (a 
40% decrease from 302.7 to 111.6 ambulance call-outs per 
month). 
NSW Fatal overdose No Inverse 43% decrease in fatal overdoses, mainly due to change in the 
number of deaths where heroin was involved. The proportion of 




NSW Fatal overdose No Inverse 15–24 years: 65% decrease 
25–34 years: 39% decrease 
35–44 years: 42% decrease 
Older age groups: no change 
Degenhardt et 
al. (2005e)
NSW Fatal overdose No Inverse 43% decrease
SA Fatal overdose No Null Small number, precluded time-series





No (purity only) Direct As heroin purity fell, ambulance call-outs fell: significant decline 
from a peak of 55 in December 1999 to an average of 8 between 
June 2001 and March 2002. 
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Table A4: Studies examining the Australian heroin shortage and the relationship between price, purity and drug-related harma (cont.)













No Inverse Mean treatment entrants per month reduced by 29%, from 285 









No Inverse Reduction in closed treatment episodes for heroin, particularly 
among younger age groups.
SA Pharmacology 
treatment




No Inverse Reduced demand for treatment, though there was a brief spike in 
demand in rural areas.
Vic Pharmacology 
treatment





No Inverse 25% decrease in number of courses of treatment, particularly 





No Inverse 15–24 years: 26% decrease in new registrations 
25–34 years: 41% decrease in new registrations 










No (purity only) Mixed As heroin purity fell, methadone treatment enrolments initially 
climbed (from around 600 in Jan 1999 to 671 in January 2001), 
then levelled off at around 640 for the remainder of that year.
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Table A4: Studies examining the Australian heroin shortage and the relationship between price, purity and drug-related harma (cont.)











NSW Property crime Yes Mixed Rise in PAP associated with short-term rise in break-and-enter 
dwelling and robbery offences, then longer term fall. But the 
offences returned to 1999 levels by June 2001.
Degenhardt et 
al. (2005b)
NSW Property crime No Mixed Robbery without a weapon increased by 33%. 
Break-and-enter dwelling increased by 14%. 




No Inverse 45% decrease
Degenhardt et 
al. (2005e) 




No Inverse Decreased, particularly pronounced among men aged 20–29 
years.




No Null No difference attributable to the shortage.
Vic Property crime No Mixed Short-term increase in residential burglary, then longer term fall.
Vic Heroin use/
possession
No Inverse 40% decrease
Smithson et 
al. (2004)
ACT Property crime No (purity only) Mixed As heroin purity fell, robbery and burglary offences initially 
increased, then declined significantly. For example, burglary fell 
from 832 in November 1999 to less than half by August 2001. No 
impact on theft. 
a: This table excludes descriptive and basic correlational studies examining the heroin shortage by Day (2004a, 2004b); Longo et al. (2004); and Mattick, Topp & Degenhardt (2004). The studies included in the table used 
interrupted time-series analyses to examine the impact of the shortage on various outcomes 
b: The studies that did not use price, purity or PAP data used the heroin shortage as an intervention point and conducted time-series analyses on outcomes, cross-referencing descriptive studies of the changes in price and purity 
during the heroin shortage (eg Day 2004a)
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